# NCI Awards CellsBin Myeloma Test SBIR

On October 27, 2026, the National Cancer Institute awarded CellsBin a Direct-to-Phase II Small Business Innovation Research (SBIR) award to advance CB-Insight, a blood-based multiple myeloma test. The work will support patient testing, validation, and preparation for potential clinical laboratory use. The award value was not disclosed, and the announcement identifies no open solicitation, so it signals federal support for diagnostic development rather than an immediate bidding opportunity.

- Diagnostic firms and clinical testing providers can treat the award as an indicator of NCI interest in validating rare-cell diagnostic technologies.
- Companies assessing this market can use CB-Insight’s planned patient testing and validation as context for future clinical-testing or technology-validation capabilities; the announcement does not specify a procurement or subcontracting opportunity.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** October 27, 2026

### Government Entities
- National Cancer Institute (NCI)

### Vendors
- CellsBin (awardee)

### Sources
- [CellsBin Receives National Cancer Institute Award to Advance Blood Test for Multiple Myeloma | Morningstar](https://www.morningstar.com/news/pr-newswire/20261027ne80952/cellsbin-receives-national-cancer-institute-award-to-advance-blood-test-for-multiple-myeloma) - Morningstar